focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chasing green goals, corporations push car fleet managers toward EVs

Thu, 08th Sep 2022 13:58

MACCLESFIELD, England, Aug 12 (Reuters) - Large corporations are jumping on the "green" bandwagon left and right, which in turn is pushing firms that lease and manage car fleets to convert to electric vehicles (EVs) faster than they had ever thought possible.

In late 2020, fleet management company ALD set a to have 30% of its new cars electrified by 2025 - a goal that seemed like a stretch because as recently as 2019 only one in 200 of ALD's new vehicles was an EV or a hybrid.

But corporate clients chasing environmental, social and governance (ESG) goals pushed the leasing giant, a unit of Societe Generale, past that target in 2021.

ALD will likely set a new goal that around 50% of its new vehicles will be either EVs or hybrid models by 2025 as corporations' hunger for zero-emission options to meet ESG targets keeps growing, Deputy Chief Executive Officer John Saffrett told Reuters.

Corporate clients are "all sitting there trying to figure out how they're going to meet their sustainability objectives," Saffrett said. "An obvious part of their footprint today that they're trying to address is their vehicle fleet."

Firms like ALD - which replaces its entire fleet every 42 months - play an important role in the auto industry, buying millions of vehicles globally that also help shape the future of the used car market when they come off lease.

ALD also leases cars to both firms and consumers on behalf of some major carmakers including Tesla Inc and Ford Motor Co.

According to industry data, leasing has grown as retail sales have fallen - the share of cars bought at retail in Europe fell to 45% in 2021 versus 55% in 2020.

BANISHING CARBON FROM SUPPLY CHAIN

France-based ALD is taking over Dutch rival LeasePlan, giving it a combined global fleet of around 3.5 million vehicles, as it focuses on scaling up its EV business.

Large ALD customers like AstraZeneca Plc have set electrification targets - the drugmaker wants its global fleet of 17,500 vehicles to be fully electric by 2025 - and are pushing carmakers to make those cars greener.

That intensifies the pressure on the auto industry to squeeze carbon and other harmful materials out of their supply chains.

But electrifying large fleets is easier said than done.

A lack of available public charging infrastructure means that for companies with sales representatives who drive long distances, only plug-in hybrids will work for now.

"The challenge you have with electrification as a corporate is you can't just switch drivers on day one," ALD's Saffrett said. "You'd love to, but it simply doesn't work."

In Africa, some parts of Asia and Europe, companies like AstraZeneca also face a lack of available EV or hybrid models.

In other areas, where a more rugged pickup truck is needed to reach the doctors served by such companies, suitable EVs are in short supply. AstraZeneca, for instance, has no choice but to buy fossil-fuel models in those regions, said Juliette White, the drugmaker's head of global sustainability.

Around 58% of AstraZeneca's global fleet are EVs, hybrids or plug-in hybrids.

"What we're absolutely clear about is if there is a plug-in hybrid or EV available, you're not getting a combustion engine model," White said at AstraZeneca's manufacturing site in Macclesfield in Northern England.

'LOW-HANGING FRUIT'

The rush to electrification is intensifying in Europe, where corporations face regulatory pressure to cut carbon footprints.

The most immediate focus is on so-called Scope 1 and Scope 2 emissions - those a company generates itself directly and indirectly. AstraZeneca's fleet, for instance, accounts for just under 17% of its emissions. At German agriculture and pharmaceuticals company Bayer, its fleet accounts for under 5% of emissions. Bayer is aiming for 30% of its global fleet of 26,000 light-duty trucks, SUVs and sedans to be electric within the next four years.

Going electric ticks both of those boxes.

"It's very low-hanging fruit and it's super easy to focus on your fleet," said Wolf-Dieter Hoppe, a Munich-based partner at consultancy Arthur D. Little.

Passenger cars and commercial vehicles are by far the largest asset class in Europe's leasing market. According to industry lobby group Leaseurope, in 2020 new vehicle leases totaled 244 billion euros ($249.5 billion), or 69% of all equipment leases.

AstraZeneca's White said large companies are also "pushing for greener and more sustainable EVs ... because otherwise what's the point?"

In Europe, EVs can also serve as a marketing tool for companies battling for qualified employees.

"Company cars can be a determining factor in the war for talent," said Piet Briers, Bayer's head of benefits. "As the availability of zero-emission car models as well as charging infrastructure continue to positively evolve, we see that employees are getting more engaged to opt for sustainable solutions."

But North America is catching up.

Again, though, the availability of suitable models and charging infrastructure will slow the adoption of EVs by corporate customers, he said.

"In 2019, I couldn't get anyone talking about this," Forbes said. "In 2022, all my clients want to talk about this evolution." ($1 = 0.9780 euro) (Reporting by Nick Carey in Macclesfield, England Editing by Matthew Lewis)

More News
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.